Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study Women with ...

The clinical significance of atypical glands suspicious for malignancy (atypia) on prostate biopsy is unclear. We studied a cohort of 139 patients with atypia who underwent repeat prostate biopsy. We ...

While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal ...

Fine needle aspiration cytology (FNAC) is a cost-efficient technique for the management of thyroid nodules. Changes in the World Health Organization classification of thyroid tumors can influence ...

More and more stereotactic vacuum-assisted breast biopsies (microbiopsies) are being performed in routine practice on infraclinical lesions. In a previous study on 2833 surgical biopsies performed for ...

Please provide your email address to receive an email when new articles are posted on . Pathologists’ concordance rates for ductal carcinoma in situ and atypical hyperplasia diagnoses were generally ...

For the 1.6 million women in the United States who undergo breast biopsy to confirm screening mammogram or breast examination findings, a diagnosis of ductal carcinoma in situ (DCIS) or atypical ...

Fine needle aspiration cytology (FNAC) is a cost-efficient technique for the management of thyroid nodules. Changes in the World Health Organization classification of thyroid tumors can influence ...

Please provide your email address to receive an email when new articles are posted on . Pathologists reviewing biopsy slides were less likely to confirm an initial diagnosis of atypia or ductal ...

Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a study has found. Atypical hyperplasia of the breast is a precancerous condition ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The ...